Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT152+153 in advanced solid tumors
NCT04710043Phase 1Completed
- Sponsor
- BioNTech SE
- Start
- Jun 2021
- Primary completion
- Sep 2025
- Modality
- Prophylactic Vaccines, Lipid-based Nanoparticles, Therapeutic Vaccines
- Countries
- 2
01
Overview
Phase 1, open-label trial of ribocytokine IL-7 BNT152 and BNT153 in solid tumor (6 arms), sponsored by BioNTech SE. Primary endpoints: Treatment-Emergent Adverse Events at 24 months, Dose Reduction and Discontinuation Due to TEAE at 24 months and 2 more. Started Jun 2021; status: completed.
02
Drugs
ribocytokine IL-7 BNT152BNT153
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04710043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04710043.